Trials success for gastroenteritis treatment

Israeli biotech Redhill has announced that the Phase 3 trial of its BEKINDA treatment for acute gastroenteritis and gastritis, on 321 patients in 21 US clinical sites, met its targets for efficacy and safety. There are some 179 million cases of gastroenteritis annually in the US.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *